Affiliations
Medical Instructor, Department of
Radiation Oncology
Duke University School of Medicine;
Physician, Department of Radiation Oncology
Durham VA Medical Center
Durham, North Carolina
Dr. Boyer has disclosed no relevant financial relationships.

Rising Kidney Cancer Cases and Emerging Treatments for Veterans

Article Type
Article
Changed
Mon, 04/21/2025 - 12:25
Display Headline

Rising Kidney Cancer Cases and Emerging Treatments for Veterans

Author(s)
Matthew J. Boyer, MD

Click here to view more from Cancer Data Trends 2025.

References

1. American Cancer Society website. Key Statistics About Kidney Cancer. Revised May 2024. Accessed December 18, 2024. https://www.cancer.org/cancer/types/kidney-cancer/about/key-statistics.html

2. American Cancer Society website. Cancer Facts & Figures 2024. 2024—First Year the US Expects More than 2M New Cases of Cancer. Published January 17, 2024. Accessed December 18, 2024.  https://www.cancer.org/research/acs-research-news/facts-and-figures-2024.html 

3.United States Department of Veterans Affairs factsheet. Pact Act & Gulf War, Post-911 Era Veterans. Published July 2023. Accessed December 18, 2024. chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.va.gov/files/2023-08/PACT%20Act%20and%20Gulf%20War%2C%20Post-911%20Veterans%20NEW%20July%202023.pdf 

4. Li M, Li L, Zheng J, Li Z, Li S, Wang K, Chen X. Liquid biopsy at the frontier in renal cell carcinoma: recent analysis of techniques and clinical application. Mol Cancer. 2023 Feb 21;22(1):37. doi:10.1186/s12943-023-01745-7

5. Bellman NL. Incidental Finding of Renal Cell Carcinoma: Detected by a Thrombus in the Inferior Vena Cava. Journal of Diagnostic Medical Sonography. 2015;31(2):118-121. doi:10.1177/8756479314546691

6. Brown JT. Adjuvant Therapy for Non-Clear Cell Renal Cell Carcinoma—The Ascent Continues. JAMA Network Open. 2024 Aug 1;7(8):e2425251. doi:10.1001/jamanetworkopen.2024.25251

7. Siva S, Louie AV, Kotecha R, et al. Stereotactic body radiotherapy for primary renal cell carcinoma: a systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS). Lancet Oncol. 2024 Jan;25(1):e18-e28. doi: 10.1016/S1470-2045(23)00513-2.

8. Choueiri TK, Tomczak P, Park SH, et al; for the KEYNOTE-564 Investigators. Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma. N Engl J Med. 2024 Apr 18;390(15):1359-1371. doi:10.1056/NEJMoa2312695

9. Bytnar JA, McGlynn KA, Kern SQ, Shriver CD, Zhu K. Incidence rates of bladder and kidney cancers among US military servicemen: comparison with the rates in the general US population. Eur J Cancer Prev. 2024 Nov 1;33(6):505-511. doi:10.1097/CEJ.0000000000000886

Author and Disclosure Information

Matthew J. Boyer, MD
Medical Instructor, Department of Radiation Oncology
Duke University School of Medicine;
Physician, Department of Radiation Oncology
Durham VA Medical Center
Durham, North Carolina
Dr. Boyer has disclosed no relevant financial relationships.

Publications
Federal Practitioner
Topics
Renal Cell Carcinoma
Oncology
Author(s)
Matthew J. Boyer, MD
Author(s)
Matthew J. Boyer, MD
Author and Disclosure Information

Matthew J. Boyer, MD
Medical Instructor, Department of Radiation Oncology
Duke University School of Medicine;
Physician, Department of Radiation Oncology
Durham VA Medical Center
Durham, North Carolina
Dr. Boyer has disclosed no relevant financial relationships.

Author and Disclosure Information

Matthew J. Boyer, MD
Medical Instructor, Department of Radiation Oncology
Duke University School of Medicine;
Physician, Department of Radiation Oncology
Durham VA Medical Center
Durham, North Carolina
Dr. Boyer has disclosed no relevant financial relationships.

Click here to view more from Cancer Data Trends 2025.

Click here to view more from Cancer Data Trends 2025.

References

1. American Cancer Society website. Key Statistics About Kidney Cancer. Revised May 2024. Accessed December 18, 2024. https://www.cancer.org/cancer/types/kidney-cancer/about/key-statistics.html

2. American Cancer Society website. Cancer Facts & Figures 2024. 2024—First Year the US Expects More than 2M New Cases of Cancer. Published January 17, 2024. Accessed December 18, 2024.  https://www.cancer.org/research/acs-research-news/facts-and-figures-2024.html 

3.United States Department of Veterans Affairs factsheet. Pact Act & Gulf War, Post-911 Era Veterans. Published July 2023. Accessed December 18, 2024. chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.va.gov/files/2023-08/PACT%20Act%20and%20Gulf%20War%2C%20Post-911%20Veterans%20NEW%20July%202023.pdf 

4. Li M, Li L, Zheng J, Li Z, Li S, Wang K, Chen X. Liquid biopsy at the frontier in renal cell carcinoma: recent analysis of techniques and clinical application. Mol Cancer. 2023 Feb 21;22(1):37. doi:10.1186/s12943-023-01745-7

5. Bellman NL. Incidental Finding of Renal Cell Carcinoma: Detected by a Thrombus in the Inferior Vena Cava. Journal of Diagnostic Medical Sonography. 2015;31(2):118-121. doi:10.1177/8756479314546691

6. Brown JT. Adjuvant Therapy for Non-Clear Cell Renal Cell Carcinoma—The Ascent Continues. JAMA Network Open. 2024 Aug 1;7(8):e2425251. doi:10.1001/jamanetworkopen.2024.25251

7. Siva S, Louie AV, Kotecha R, et al. Stereotactic body radiotherapy for primary renal cell carcinoma: a systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS). Lancet Oncol. 2024 Jan;25(1):e18-e28. doi: 10.1016/S1470-2045(23)00513-2.

8. Choueiri TK, Tomczak P, Park SH, et al; for the KEYNOTE-564 Investigators. Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma. N Engl J Med. 2024 Apr 18;390(15):1359-1371. doi:10.1056/NEJMoa2312695

9. Bytnar JA, McGlynn KA, Kern SQ, Shriver CD, Zhu K. Incidence rates of bladder and kidney cancers among US military servicemen: comparison with the rates in the general US population. Eur J Cancer Prev. 2024 Nov 1;33(6):505-511. doi:10.1097/CEJ.0000000000000886

References

1. American Cancer Society website. Key Statistics About Kidney Cancer. Revised May 2024. Accessed December 18, 2024. https://www.cancer.org/cancer/types/kidney-cancer/about/key-statistics.html

2. American Cancer Society website. Cancer Facts & Figures 2024. 2024—First Year the US Expects More than 2M New Cases of Cancer. Published January 17, 2024. Accessed December 18, 2024.  https://www.cancer.org/research/acs-research-news/facts-and-figures-2024.html 

3.United States Department of Veterans Affairs factsheet. Pact Act & Gulf War, Post-911 Era Veterans. Published July 2023. Accessed December 18, 2024. chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.va.gov/files/2023-08/PACT%20Act%20and%20Gulf%20War%2C%20Post-911%20Veterans%20NEW%20July%202023.pdf 

4. Li M, Li L, Zheng J, Li Z, Li S, Wang K, Chen X. Liquid biopsy at the frontier in renal cell carcinoma: recent analysis of techniques and clinical application. Mol Cancer. 2023 Feb 21;22(1):37. doi:10.1186/s12943-023-01745-7

5. Bellman NL. Incidental Finding of Renal Cell Carcinoma: Detected by a Thrombus in the Inferior Vena Cava. Journal of Diagnostic Medical Sonography. 2015;31(2):118-121. doi:10.1177/8756479314546691

6. Brown JT. Adjuvant Therapy for Non-Clear Cell Renal Cell Carcinoma—The Ascent Continues. JAMA Network Open. 2024 Aug 1;7(8):e2425251. doi:10.1001/jamanetworkopen.2024.25251

7. Siva S, Louie AV, Kotecha R, et al. Stereotactic body radiotherapy for primary renal cell carcinoma: a systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS). Lancet Oncol. 2024 Jan;25(1):e18-e28. doi: 10.1016/S1470-2045(23)00513-2.

8. Choueiri TK, Tomczak P, Park SH, et al; for the KEYNOTE-564 Investigators. Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma. N Engl J Med. 2024 Apr 18;390(15):1359-1371. doi:10.1056/NEJMoa2312695

9. Bytnar JA, McGlynn KA, Kern SQ, Shriver CD, Zhu K. Incidence rates of bladder and kidney cancers among US military servicemen: comparison with the rates in the general US population. Eur J Cancer Prev. 2024 Nov 1;33(6):505-511. doi:10.1097/CEJ.0000000000000886

Publications
Federal Practitioner
Publications
Federal Practitioner
Topics
Renal Cell Carcinoma
Oncology
Article Type
Article
Display Headline

Rising Kidney Cancer Cases and Emerging Treatments for Veterans

Display Headline

Rising Kidney Cancer Cases and Emerging Treatments for Veterans

Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Eyebrow Default
SLIDESHOW
Gate On Date
Thu, 04/03/2025 - 19:46
Un-Gate On Date
Thu, 04/03/2025 - 19:46
Use ProPublica
CFC Schedule Remove Status
Thu, 04/03/2025 - 19:46
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Article Slideshow Optional Introduction

Cases of kidney cancer, also known as renal cell carcinoma (RCC), are increasing, with more than 81,600 expected diagnoses in 2024, largely due to improved imaging and rising rates of risk factors, including obesity, hypertension, and diabetes.1,2 Veterans, particularly those exposed to chemicals and perfluoroalkyl and polyfluoroalkyl substances (PFAS), face a higher risk for RCC. Under the PACT Act, RCC may be recognized as service-related for Gulf War and post-9/11 veterans.3,4

RCC accounts for more than 90% of kidney cancers and is often asymptomatic, making early detection reliant on an incidental finding on imaging.4,5 Treatment for localized RCC typically involves surgery, with adjuvant immunotherapy for high-risk cases, though up to 50% of patients may still experience recurrence.6 Emerging treatments like stereotactic body radiotherapy (SBRT) are gaining attention for managing inoperable or high-risk RCC as it has demonstrated high rates of effectiveness, local control, and strong survival outcomes; however, further comparison with surgical options is needed.7 Advances in adjuvant therapies for kidney cancer emphasize the potential to extend survival for high-risk patients post-surgery, but balancing the benefits with risks of this treatment remains crucial.8

Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date
Thu, 04/03/2025 - 19:46
Slide Media
Subscribe to Matthew J. Boyer, MD